Par Believes It Holds 180-Day Exclusivity For AndroGel Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson also maintains it holds first-to-file exclusivity for a generic version of Solvay’s testosterone replacement gel, Par says. Solvay’s patent infringement suit against Par is expected to go to trial in the fourth quarter of 2005.
You may also be interested in...
Auxilium Testim Has 8.9% Share Of Testosterone Gel Scripts – IPO Prospectus
The company is positioning Testim as offering a convenience and cost advantage over the only other gel product, Solvay's Androgel, and an efficacy advantage over Watson's Androderm testosterone patch.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles